003020 立方制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)6.8399.38214.32215.03313.901
总资产报酬率 ROA (%)4.6666.3369.84411.02510.729
投入资产回报率 ROIC (%)6.5208.99112.95213.10412.281

边际利润分析
销售毛利率 (%)64.56369.16151.48337.38539.906
营业利润率 (%)12.68711.70513.4309.3078.466
息税前利润/营业总收入 (%)12.69811.30013.3699.1608.500
净利润/营业总收入 (%)11.39210.04212.3048.1127.576

收益指标分析
经营活动净收益/利润总额(%)74.05494.58884.75884.45390.612
价值变动净收益/利润总额(%)20.2517.56810.80013.4495.761
营业外收支净额/利润总额(%)-0.175-3.4450.834-0.0971.222

偿债能力分析
流动比率 (X)2.2102.0372.1212.3333.718
速动比率 (X)1.7081.6581.6731.7523.142
资产负债率 (%)25.10926.04024.56830.24122.129
带息债务/全部投入资本 (%)1.7242.9881.49314.4626.599
股东权益/带息债务 (%)5,531.9703,188.4956,459.033584.0271,370.653
股东权益/负债合计 (%)275.810258.085276.234230.675351.900
利息保障倍数 (X)374.979-758.353-77.149-66.620-120.756

营运能力分析
应收账款周转天数 (天)90.14374.38054.86542.12140.994
存货周转天数 (天)172.928178.119118.02461.36750.420